Immune cells engineered to fight ovarian cancer enter human testing
NCT ID NCT03393962
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This early-stage trial tests a new treatment for ovarian cancer using specially engineered immune cells (OC-EIEs) designed to recognize and attack cancer cells. About 20 women with advanced ovarian cancer will receive the therapy to see if it is safe and can shrink tumors. The goal is to control the disease, not necessarily cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinshazhou Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, 510415, China
-
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, 518000, China
-
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center
Kunming, Yunnan, 650000, China
Conditions
Explore the condition pages connected to this study.